Gosogliptin

Identification

Generic Name
Gosogliptin
DrugBank Accession Number
DB08382
Background

Gosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 366.4089
Monoisotopic: 366.19796583
Chemical Formula
C17H24F2N6O
Synonyms
  • 2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
  • Gosogliptin
External IDs
  • PF-00734200
  • PF-734,200
  • PF-734200

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ADipeptidyl peptidase 4Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Gosogliptin.
AcebutololThe therapeutic efficacy of Gosogliptin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Gosogliptin can be increased when used in combination with Acetazolamide.
AcetohexamideGosogliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Gosogliptin can be increased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid amides
Alternative Parents
N-arylpiperazines / Pyrrolidinecarboxamides / Dialkylarylamines / N-acylpyrrolidines / Aminopyrimidines and derivatives / N-alkylpiperazines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds
show 7 more
Substituents
1,4-diazinane / Alkyl fluoride / Alkyl halide / Alpha-amino acid amide / Amine / Aminopyrimidine / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
GI718UO477
CAS number
869490-23-3
InChI Key
QWEWGXUTRTXFRF-KBPBESRZSA-N
InChI
InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
IUPAC Name
2-{4-[(3S,5S)-5-(3,3-difluoropyrrolidine-1-carbonyl)pyrrolidin-3-yl]piperazin-1-yl}pyrimidine
SMILES
[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1

References

General References
Not Available
PubChem Compound
11516136
PubChem Substance
99444853
ChemSpider
9690926
BindingDB
50249479
ChEMBL
CHEMBL515387
ZINC
ZINC000023247686
PDBe Ligand
PF2
Wikipedia
Gosogliptin
PDB Entries
3f8s

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus2
1CompletedTreatmentRenal Insufficiency,Chronic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.33 mg/mLALOGPS
logP0.17ALOGPS
logP0.4Chemaxon
logS-2.4ALOGPS
pKa (Strongest Basic)9.38Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area64.6 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity93.03 m3·mol-1Chemaxon
Polarizability36.63 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8873
Caco-2 permeable-0.6669
P-glycoprotein substrateSubstrate0.648
P-glycoprotein inhibitor IInhibitor0.6514
P-glycoprotein inhibitor IINon-inhibitor0.6933
Renal organic cation transporterInhibitor0.5225
CYP450 2C9 substrateNon-substrate0.8559
CYP450 2D6 substrateNon-substrate0.6078
CYP450 3A4 substrateSubstrate0.5847
CYP450 1A2 substrateInhibitor0.6332
CYP450 2C9 inhibitorInhibitor0.5428
CYP450 2D6 inhibitorNon-inhibitor0.7807
CYP450 2C19 inhibitorNon-inhibitor0.5508
CYP450 3A4 inhibitorNon-inhibitor0.6445
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5971
Ames testNon AMES toxic0.6791
CarcinogenicityNon-carcinogens0.9048
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.6944 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8928
hERG inhibition (predictor II)Inhibitor0.9126
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0019000000-8a02289ac56ddaa6e95f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0009000000-96316ffa406454ef3fde
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-1029000000-ce90638f41ea43895de1
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0029000000-54695b21e83e694a56fc
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01q0-0579000000-9a8eb8dc88e8ecb504bc
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-1937000000-2122a1394d574f5c7793
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-182.04768
predicted
DeepCCS 1.0 (2019)
[M+H]+184.44325
predicted
DeepCCS 1.0 (2019)
[M+Na]+190.35579
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details
1. Dipeptidyl peptidase 4
Kind
Protein
Organism
Humans
Pharmacological action
Yes
General Function
Virus receptor activity
Specific Function
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by bindi...
Gene Name
DPP4
Uniprot ID
P27487
Uniprot Name
Dipeptidyl peptidase 4
Molecular Weight
88277.935 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
  2. Dai H, Johnson SL, Terra SG, Marbury TC, Smith WB, Alcorn H, Boyd RA, Wang R, Nguyen TT: The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency. Br J Clin Pharmacol. 2011 Jul;72(1):85-91. doi: 10.1111/j.1365-2125.2011.03954.x. [Article]

Drug created at September 15, 2010 21:31 / Updated at February 21, 2021 18:52